A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors

Jun-Chen Liu; Hong-Jing Yu

doi:10.2147/PGPM.S391756

A Review of the Pharmacokinetic Characteristics of Immune Checkpoint Inhibitors and Their Clinical Impact Factors

Pharmgenomics Pers Med. 2023 Jan 20:16:29-36. doi: 10.2147/PGPM.S391756. eCollection 2023.

Authors

Jun-Chen Liu¹, Hong-Jing Yu¹

Affiliation

¹ Department of Clinical Pharmacy, The First People's Hospital of Jiande, Jiande, People's Republic of China.

Abstract

Immune checkpoint inhibitors (ICIs) have been shown to be significant in improving the overall survival rate in certain malignancies with poor prognoses. However, only 20-40% of patients achieve long-term benefits, highlighting the relevance of the factors that influence the treatment, which can help clinicians improve their results and guide the development of new immune checkpoint therapies. In this study, the current pharmacokinetic aspects associated with the ICIs and the factors influencing clinical efficacy were characterised, including in terms of drug metabolism, drug clearance, hormonal effects and immunosuppressive effects.

Keywords: immune checkpoint inhibitors; influencing factors; pharmacokinetics.

Publication types

Review

Grants and funding

This work was supported by Zhejiang Province Medical and Health Science and Technology Program[Grant NO.:2020KY808].